WASHINGTON and LONDON, Feb. 11, 2020
About TauC3 Biologics Limited:
TauC3 Biologics is a privately held British biopharmaceutical company developing an exceptionally potent and specific, humanized monoclonal antibody, uniquely targeting an especially noxious protein metabolite in the brain of patients with Alzheimer's disease and Progressive Supranuclear Palsy. The company believes that the antibody has the potential to be a standout immunotherapy for these diseases whereas other more advanced tau programs are unlikely to be as efficacious and pose potential safety concerns. The humanized antibody was generated in partnership with LifeArc, a UK medical research charity. Find out more about us at www.tauc3bio.com
About LifeArc
LifeArc is a self-funded medical research charity. Our mission is to advance translation of early science into health care treatments or diagnostics that can be taken through to full development and made available to patients. We have been doing this for more than 25 years and our work has resulted in a diagnostic for antibiotic resistance and four licensed medicines.
Our success allows us to explore new approaches to stimulate and fund translation. We have our own drug discovery and diagnostics development facilities, supported by experts in technology transfer and intellectual property who also provide services to other organisations. Our model is built on collaboration, and we partner with a broad range of groups including medical research charities, research organisations, industry and academic scientists. We are motivated by patient need and scientific opportunity.
Find out more about our work on www.lifearc.orgor follow us on LinkedInor Twitter.
About AD
AD is the most common cause of dementia and represents an enormous and growing global public health challenge. It is a uniformly fatal neurodegenerative disorder with no cure or substantially effective treatment. AD currently affects more than 5 million Americans, 7 million Europeans and, in total, about 44 million people worldwide according to the most recent report by the Alzheimer's Association with an estimated cost of more than one percent of global GDP. No disease-modifying treatments have been approved.
About PSP
PSP is a rare and fatal degenerative neurological disorder affecting about 20,000 people in the United States. It causes progressive impairment of balance and walking; impaired eye movement, abnormal muscle tone, speech difficulties, and problems related to swallowing and eating. Affected individuals also frequently experience personality changes and cognitive impairment. Symptoms typically begin after age 60 but can begin earlier. The exact cause of PSP is unknown. PSP is often misdiagnosed as Parkinson disease, AD, cotrimoxazole degeneration and other neurodegenerative disorders. No disease-modifying treatments have been approved.
Contacts
Daniel G. Chain, PhD, President & CEO, TauC3 Biologics; dchain@tauC3bio.com; +44 (0)203 743 3938
